Non-coding RNA Markers and Epigenetic Modifications in Tumor Identification

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "RNA".

Deadline for manuscript submissions: closed (25 April 2022) | Viewed by 3000

Special Issue Editor


E-Mail Website
Guest Editor
Inflammation, Repair and Development Department, Imperial College London, London, UK
Interests: gene regulation; epigenetics; non-coding RNAs; cancer; lung diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the last decade, the discovery of non-coding RNAs’ deregulation in different cancer cells has been the focus of attention for numerous investigations. The emergence of deep sequencing technologies has generated a high amount of public data available to further explore the role of ncRNAs, as well as epigenetic modifications (i.e., chromatin remodeling) in early diagnostics and stratification of patients. Therefore, there is a large amount of interest in the study of non-coding RNAs and epigenetic regulators to personalize clinical practice and be able to apply more specific and effective treatments to cancer patients.

For instance, miRNAs are negative modulators of gene expression since they bind to mRNAs of different genes. Thus, these ncRNAs are linked to gene regulatory networks. Moreover, miRNAs functionally cooperate with ncRNA molecules, such as circRNAs and lncRNAs, to control their cellular presence. The alterations of this equilibrium have a very important outcome that affects the cellular fate, since important imbalances can propitiate the development of diseases.

Their tissue-specific expression and stable structure make them ideal candidates that may allow identifying tumor subtypes in an accurate manner. Their potential as biomarkers, not only for diagnostic and prognostic purposes but also as therapeutic targets for this disease, makes them valuable molecules for research.

This Special Issue aims to shed some light on the use of novel candidates for tumor identification and strategies involving non-coding RNAs and epigenetic modifications, as well as describe new advances obtained in clinics. Original research manuscripts and comprehensive reviews are welcome to this call.

Dr. Elena Lopez-Jimenez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNAs
  • non-coding RNAs
  • biomarkers
  • gene regulation
  • cancer
  • therapeutic targets
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 1059 KiB  
Review
Role of Chromatin Replication in Transcriptional Plasticity, Cell Differentiation and Disease
by Elena López-Jiménez and Cristina González-Aguilera
Genes 2022, 13(6), 1002; https://doi.org/10.3390/genes13061002 - 2 Jun 2022
Cited by 5 | Viewed by 2483
Abstract
Chromatin organization is essential to maintain a correct regulation of gene expression and establish cell identity. However, during cell division, the replication of the genetic material produces a global disorganization of chromatin structure. In this paper, we describe the new scientific breakthroughs that [...] Read more.
Chromatin organization is essential to maintain a correct regulation of gene expression and establish cell identity. However, during cell division, the replication of the genetic material produces a global disorganization of chromatin structure. In this paper, we describe the new scientific breakthroughs that have revealed the nature of the post-replicative chromatin and the mechanisms that facilitate its restoration. Moreover, we highlight the implications of these chromatin alterations in gene expression control and their impact on key biological processes, such as cell differentiation, cell reprogramming or human diseases linked to cell proliferation, such as cancer. Full article
Show Figures

Figure 1

Back to TopTop